Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Episodic ataxia type 2.

Michael Strupp1, Andreas Zwergal, Thomas Brandt

  • 1Department of Neurology, University of Munich, Munich, Germany. Michael.Strupp@med.uni-muenchen.de

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|March 31, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Epidemiology and Clinical Presentation of the Acute Imbalance Syndrome (AIS)-A Systematic Review and Meta-Analysis.

European journal of neurology·2026
Same author

Prevalence and direct costs of vestibular disease in France - matched case-control study results from the 2022 and 2023 french health data system.

Cost effectiveness and resource allocation : C/E·2026
Same author

Confirmatory factor analysis and Rasch analysis of the German revised version of the Niigata PPPD questionnaire: NPQ-R.

Frontiers in neurology·2026
Same author

Gabapentin Utilization and Adverse Effects Among US Hemodialysis Patients Diagnosed With Pruritus or Neuropathic Pain.

Kidney medicine·2026
Same author

Detection of Focal Lesions in Epilepsy with [<sup>18</sup>F]UCB-H Synaptic Vesicle Protein 2A PET Imaging.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Superior oblique myokymia: diagnostic criteria and long-term outcome.

Journal of neurology·2026
Same journal

FGF17 synergistically targets neuronal survival and oligodendrogenesis to restore stroke deficits.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Sotagliflozin improves cognitive deficits and attenuates neuroinflammation of Alzheimer's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Neurological complications of current and emerging CAR-T cell therapies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Hemodynamics Beyond Ischemic Zone Underlies Early Neurological Deterioration in Minor Stroke with Large Vessel Occlusion.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Nervonic acid and the long arc of therapeutic hope in X-linked adrenoleukodystrophy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Long-term efficacy of subthalamic nucleus deep brain stimulation in focal motor seizures and implications for candidate selection.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
See all related articles

Episodic ataxia type 2 (EA 2) is a rare neurological disorder caused by calcium channel gene mutations. Acetazolamide and 4-aminopyridine are treatments, with 4-aminopyridine showing promise in preventing attacks.

Area of Science:

  • Neurology
  • Genetics
  • Channelopathies

Background:

  • Episodic ataxia type 2 (EA 2) is an autosomal dominant neurological disorder.
  • It results from voltage-gated calcium channel dysfunction, primarily CACNA1A gene mutations.
  • Patients experience recurrent ataxia, vertigo, and imbalance, with persistent downbeat nystagmus between attacks.

Purpose of the Study:

  • To review the pathophysiology and treatment of Episodic Ataxia type 2.
  • To discuss the efficacy of acetazolamide and 4-aminopyridine in managing EA 2 symptoms.

Main Methods:

  • Literature review of EA 2 pathophysiology and treatment options.
  • Analysis of clinical trial data for acetazolamide and 4-aminopyridine efficacy.

Main Results:

Related Experiment Videos

  • EA 2 is linked to CACNA1A mutations affecting P/Q-type calcium channels in Purkinje cells.
  • Acetazolamide (ACTZ) is effective in ~70% of patients, but effects can be transient.
  • 4-aminopyridine (4-AP) showed promise in preventing attacks by enhancing Purkinje cell excitability.

Conclusions:

  • Further research is needed to clarify EA 2 pathophysiology and the mechanisms of ACTZ and 4-AP.
  • 4-AP demonstrates potential as an effective treatment for preventing EA 2 attacks.